Case Report Forms (CRF)

Protocol: PROTO-2661 - A Phase IV Study of Psoriasis Treatment

Version 1.5 - Generated 2025-04-19

STUDY OVERVIEW

Protocol Number:	PROTO-2661	Therapeutic Area:	Dermatology
Study Title:	A Phase IV Study of Psoriasis Treatme	ntIndication:	Psoriasis
Study Design:	Non-randomized, Open-label, Dose-eso	calleation ber of Subjects:	732
Study Duration:	6 weeks	Number of Sites:	40

This document contains blank Case Report Forms (CRFs) for clinical trial data collection. These forms are provided for educational purposes to practice SDTM annotation. Each form represents a different aspect of clinical data collection that would be mapped to SDTM domains.

TABLE OF CONTENTS

- 1. Screening/Eligibility
- 2. Demographics
- 3. Medical History
- 4. Physical Examination
- 5. Vital Signs
- 6. ECG Assessment
- 7. Laboratory Tests
- 8. Concomitant Medications
- 9. Study Treatment Administration
- 10. Adverse Events
- 11. Serious Adverse Events
- 12. Efficacy Assessments
- 13. Quality of Life Questionnaire
- 14. Study Completion/Early Termination
- 15. Protocol Deviation
- 16. Hospitalization
- 17. Disease-Specific Assessments

GENERAL INSTRUCTIONS

- Complete all required fields in each form
- Use black or blue ink
- Write legibly in BLOCK CAPITALS
- For dates, use DD/MMM/YYYY format (e.g., 01/JAN/2025)
- Cross out errors with a single line, initial and date the correction
- Do not use correction fluid or tape
- The investigator or authorized delegate must sign and date all completed forms

Page 1 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

SCREENING/ELIGIBILITY FORM

Complete the following Screening	g/Eligibility inforr	nation
Eligibility Assessment Date:/	/ /	(DD/MMM/YYYY)

INCLUSION CRITERIA

No.	Inclusion Criterion	Yes	No
1.	Inclusion criterion #1 text		
2.	Inclusion criterion #2 text		
3.	Inclusion criterion #3 text		
4.	Inclusion criterion #4 text		
5.	Inclusion criterion #5 text		

EXCLUSION CRITERIA

No.	Exclusion Criterion	Yes	No
1.	Exclusion criterion #1 text		
2.	Exclusion criterion #2 text		
3.	Exclusion criterion #3 text		
4.	Exclusion criterion #4 text		
5.	Exclusion criterion #5 text		

ELIGIBILITY DETERMINATION

Does the subject meet all inclusion criteria and none of the exclusion criteria?

■ Yes, subject is eligible ■ No, subject is not eligible

Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 2 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

DEMOGRAPHICS FORM

Complete at screening visit

Date of Birth:	/ (DD/MMM/YYYY)
Sex:	■ Male ■ Female
Race:	■ White ■ Black or African American ■ Asian ■ American Indian or Alaska Native ■ Other
Ethnicity:	■ Hispanic or Latino ■ Not Hispanic or Latino
Height:	cm
Weight:	kg
Body Mass Index (BMI):	kg/m²

Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 3 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

MEDICAL HISTORY FORM

Record all relevant medical history. In	nclude significant past and ongoing conditions.
---	---

Medical Condition/Disease:

Start Date (DD/MMM/YYYY):	// I Unknown	End Date (DD/MMM/YYYY):	/ / ■ Ongoing
Is condition currently active?	■ Yes ■ No	Severity:	■ Mild ■ Moderate ■ Severe
Treatment for condition:	■ Yes ■ No	If Yes, specify:	

Additional Details (diagnosis, symptoms, relevant tests, procedures, etc.):

Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 4 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

PHYSICAL EXAMINATION FORM

Examination Date:	/ /	′	(DD/MMM/YYYY)	1
Litarrilliation Date.	/		(1

Body System	Normal	Abnorma I	Not Examined	If Abnormal, provide details
General Appearance				
Skin				
HEENT				
Lymph Nodes				
Cardiovascular				
Respiratory				
Abdomen				
Musculoskeletal				
Neurological				
Other (specify):				

Are any abnormal findings clinically significant	t? ■ Yes ■ No

Additional Comments:

Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 5 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

	sition: ■ Sitting ■ Supine ■ St	Result	Units	Clinically Significant
	Temperature	1100011	°C	■ Yes ■ No
	Systolic Blood Pressure		mmHg	■ Yes ■ No
	Diastolic Blood Pressure		mmHg	■ Yes ■ No
	Heart Rate		bpm	■ Yes ■ No
	Respiratory Rate		breaths/min	■ Yes ■ No
	Weight		kg	■ Yes ■ No
	Height		cm	■ Yes ■ No
lf a	any clinically significant finding	s, please specify:		
	Name of Person Completing	Form:		
	Signature:			
	Date (DD/MMM/YYYY):			

Page 6 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

Position: ■ Supine ■ S	Semi-recumbent ■ Of	ther (specify):		
Parameter	Result	Units	Reference Range	Abnormal
Heart Rate		bpm		■ Yes ■ No
PR Interval		msec		■ Yes ■ No
QRS Duration		msec		■ Yes ■ No
QT Interval		msec		■ Yes ■ No
QTc Interval		msec		■ Yes ■ No
Overall Interpretation: I Normal ■ Abnormal, abnormal, describe a	, ,	ant ■ Abnorma	al, clinically significant	
Name of Person C	ompleting Form:			
Signature:				
Date (DD/MMM/YY	YY):			

Page 7 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

LABORATORY TESTS FORM

Sample Collection Date and Time://	: (DD/MMM/YYYY HH:MM 24-hour format)
Sample Type: ■ Blood ■ Urine ■ Other (specify):	
Fasting Status: ■ Fasting (>8 hours) ■ Non-fasting	

Test	Result	Units	Reference Range	Abnormal
HEMATOLOGY				
Hemoglobin				■ High ■ Low ■ Normal
Hematocrit				■ High ■ Low ■ Normal
Red Blood Cells (RBC)			_	■ High ■ Low ■ Normal
White Blood Cells (WBC)			_	■ High ■ Low ■ Normal
Neutrophils				■ High ■ Low ■ Normal
Lymphocytes				■ High ■ Low ■ Normal
Monocytes				■ High ■ Low ■ Normal
Eosinophils				■ High ■ Low ■ Normal
Basophils				■ High ■ Low ■ Normal
Platelets				■ High ■ Low ■ Normal
CHEMISTRY				
Glucose				■ High ■ Low ■ Normal
BUN			_	■ High ■ Low ■ Normal
Creatinine			_	■ High ■ Low ■ Normal
Total Bilirubin			_	■ High ■ Low ■ Normal
AST				■ High ■ Low ■ Normal
ALT			_	■ High ■ Low ■ Normal
Alkaline Phosphatase			_	■ High ■ Low ■ Normal
Total Protein				■ High ■ Low ■ Normal
Albumin			_	■ High ■ Low ■ Normal
Sodium				■ High ■ Low ■ Normal
Potassium				■ High ■ Low ■ Normal
Chloride			_	■ High ■ Low ■ Normal
Calcium			_	■ High ■ Low ■ Normal

Comments on clinically significant findings	: :
Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 8 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

CONCOMITANT MEDICATIONS FORM

Start Date (DD/MMM/YYYY):	/	End Date (DD/MMM/YYYY):	/ /■ Ongoing
Dose:		Units:	
Frequency:	■ Once ■ BID ■ TID ■ QID ■ PRN ■ Other (specify):	Route:	■ Oral ■ IV ■ IM ■ SC ■ Topical ■ Other (specify):
Indication:			
Taken for Adverse Event?			
■ Yes (specify AE):		■ No	
Comments:			
Name of Person Comp	oleting Form:		
Signature:			
Date (DD/MMM/YYYY):		

Page 9 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

STUDY TREATMENT ADMINISTRATION FORM

Stud	y Treatment Name:			
	Administration Date (DD/MMM/YYYY):	/	Administration Time:	: (24-hour format)
[Dose Level:		Units:	
F	Route:	■ Oral ■ IV ■ IM ■ SC ■ Other:	Batch/Lot Number:	
	Dose administered completely?	■ Yes ■ No	If No, actual dose administered:	
	there a compliance issue?	P ■ Yes ■ No		
■ Ac	dverse Event ■ Protocol De	eviation ■ Lost Medication ■	=	
Com	ments:			
1	Name of Person Completin	g Form:		
(Signature:			
	Date (DD/MMM/YYYY):			

Page 10 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

ADVERSE EVENTS FORM

Ad	verse Event Term:			
	Start Date (DD/MMM/YYYY):	//	End Date (DD/MMM/YYYY):	/
	Severity/Intensity:	■ Mild ■ Moderate ■ Severe	Action Taken with Study Treatment:	■ None ■ Interrupted ■ Discontinued
	Serious:	■ Yes ■ No	If Yes, SAE Report Completed:	■ Yes ■ No ■ N/A
	Relationship to Study Treatment:	■ Not Related ■ Unlikely ■ Possible ■ Probable ■ Definite	Outcome:	■ Recovered/Resolved ■ Recovering/Resolving ■ Not Recovered/Not Resolved ■ Recovered with Sequelae ■ Fatal ■ Unknown
	Disability/Incapacity ■ Conge Important Medical Event ■ C			
,				
	Name of Person Completin	g Form:		
	Signature:			
	Date (DD/MMM/YYYY):			

Page 11 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

SERIOUS ADVERSE EVENTS FORM

Assessment Date:/	/ (DD/MMM/YY	YY)		
Serious Adverse Events	Details:			
Parameter	Value/Finding	Units	Comments	
	_			
	_			
Additional Notes/Comm	ents:			
Name of Person Co	mpleting Form:			
Signature:				
Date (DD/MMM/YY)	YY):			

Page 12 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

EFFICACY ASSESSMENTS FORM

	Result/Score	Units	Clinically Significant Change
		_	
			Yes ■ No ■ N/A
			Yes ■ No ■ N/A
			Yes ■ No ■ N/A
			Yes ■ No ■ N/A
			Yes ■ No ■ N/A
			Yes ■ No ■ N/A
			■ Yes ■ No ■ N/A
ments on assessments:	1	ı	1

Page 13 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

QUALITY OF LIFE QUESTIONNAIRE FORM

sessment Date:/				
estionnaire Type: ■ SF-3	6 ■ EQ-5D ■ F <i>i</i>	ACT ■ Other:		
Domain	Score	Range	Comments	
Physical Functioning				
Role-Physical				
Bodily Pain				
General Health				
Vitality				
Social Functioning				
Role-Emotional				
Mental Health				
Overall Score				
Name of Person Comple	eting Form:			
Signature:	-			

Page 14 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

STUDY COMPLETION/EARLY TERMINATION FORM

Date of Assessment: / / (Di	D/MMM/YYYY)
Study Status: ■ Completed ■ Early Termination	
If Early Termination, primary reason: ■ Adverse Event ■ Death ■ Protocol Violation ■ Withdrawal of Consent ■ Study Terminate	
■ Other (specify): If Adverse Event, specify:	
Were all End of Study procedures completed If No, specify procedures not completed and	
II No, specify procedures not completed and	Teason.
Name of Person Completing Form:	
Signature:	
Date (DD/MMM/YYYY):	

Page 15 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

PROTOCOL DEVIATION FORM

Со	mplete the following Protoco	ol Deviation information			
Ass	sessment Date://	(DD/MMM/YYYY)			
Pro	otocol Deviation Details:				
	Parameter	Value/Finding	Units	Comments	
					_
					-
					-
					_
					-
					-
					-
					_
					_
					_
Ade	ditional Notes/Comments:				
Γ	Name of Dances Commission				
-	Name of Person Completin	ig Form:			
	Signature:				
	Date (DD/MMM/YYYY):				

Page 16 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

HOSPITALIZATION FORM

Complete the following Ho	penitalization information			
		VV\		
	/ (DD/MMM/YY	11)		
Hospitalization Details:				
Parameter	Value/Finding	Units	Comments	
Additional Notes/Commer	nts:			
Name of Person Com	pleting Form:			
	picting Fulli.			
Signature:				
Date (DD/MMM/YYYY)	/):			

Page 17 of 17

Protocol ID:	PROTO-2661	Site ID:	
Subject ID:		Visit:	

DISEASE-SPECIFIC ASSESSMENTS FORM

Complete the following Diseas	e-Specific Assessments in	nformation		
Assessment Date://	(DD/MMM/YYY)	Y)		
Disease-Specific Assessments	s Details:			
Parameter	Value/Finding	Units	Comments	
				-
				_
				_
				_
				-
				_
				-
				-
				-
				-
Additional Notes/Comments:				
Name of Person Completi	na Form:			
Signature:	<u> </u>			
Date (DD/MMM/YYYY):				